Wegovy is a weight-loss jab manufactured by Novo Nordisk. It’s a weekly weight-loss injection with semaglutide as the active ingredient.
Semaglutide is a GLP-1 receptor agonist that helps reduce hunger and appetite, allowing you to eat fewer calories, lose weight, and manage your blood sugar levels.
Wegovy is approved in the UK for individuals living with obesity to help them eat fewer calories and lose weight. Still, you’ll also experience improved glycemic control due to the effect of GLP-1s on insulin function.
Wegovy was initially approved as a prescription medication and is now widely available online for private purchase in the U.S.
Wegovy launched in the UK in September 2023. Still, its supply has been limited with prioritisation given to NHS patients currently on Saxenda, with a controlled supply also available for private companies, like Second Nature.
Can I get Wegovy on the NHS?
The NHS is initially prioritising Wegovy for individuals currently on Saxenda.
The NHS is also developing pilots to provide Wegovy to individuals on specialised weight management programmes, but there’s no confirmation of when these programmes will launch.
To get a Wegovy prescription on the NHS, you must meet strict eligibility criteria such as a BMI over 35 or a BMI over 30 with at least one obesity-related comorbidity.
Wegovy is taken once a week via a self-administered injection.
Wegovy is available in the U.S. and via prescription from your GP in the UK if you’re taking Saxenda to support weight loss. It will also be available from private companies alongside lifestyle change programmes, like Second Nature.
Should I buy Wegovy online?
Wegovy is designed as an additional tool for weight management and shouldn’t be considered a lifelong medication.
Instead, it should be used to help you kickstart your weight loss and healthy journey while you commit to living a healthier lifestyle.
Ideally, we’d be able to lose weight without medication and lifestyle changes would be enough to support weight loss in the long term.
We’d generally recommend trying Second Nature’s weight-loss programme before considering a weight-loss jab.
Changing your habits is the most sustainable way to achieve long-term weight loss, and it’s also less expensive.
At Second Nature, we’ve been trusted by the NHS since 2017 to support people with type 2 diabetes and obesity to lose weight, manage their blood sugar levels, and lead healthier lifestyles for the long term.
In 2022, the NHS published data in the BMJ that compared the weight loss outcomes of five providers in the National Diabetes Prevention Programme.
Second Nature was more than twice as effective at supporting weight loss than the other four providers.
However, if you’ve decided to try Wegovy (when it’s available) but need support in making positive changes to your lifestyle, Second Nature could be an option for you. But it’s worth noting that we have strict eligibility criteria.
Otherwise, keep reading as we dig into the science of Wegovy and how GLP-1s work.
1) How does Wegovy work?
When we eat food, our stomach releases a hormone that helps the body regulate hunger and blood sugar levels. This hormone is called GLP-1 (glucagon-like peptide-1). The actions of GLP-1 are the target of Wegovy.
Wegovy and this class of medications are known as GLP-1 receptor agonists (GLP-1s). They mimic the actions of the hormone GLP-1.
Wegovy helps your pancreas release more insulin to lower blood sugar levels, delay emptying food from the stomach (also called gastric emptying), and lowers hunger by communicating directly with the brain’s appetite control centre, the hypothalamus, to lower food-seeking behaviours.
Click here to learn more about how GLP-1 receptor agonists like semaglutide work.
- Wegovy is a GLP-1 receptor agonist and mimics the hormone called GLP-1 to lower blood sugar levels by helping the pancreas release the hormone insulin
- Wegovy lowers hunger by communicating directly with the brain’s appetite control centre, the hypothalamus. This action lowers food-seeking behaviour.
- Wegovy also slows gastric emptying, which means that food will take longer to move from the stomach and through your digestive system
2) How much weight will I lose on Wegovy?
Wegovy leads to an average weight loss of 15-20% after 68 weeks and is more effective than other weight-loss injections, like Saxenda.
A meta-analysis investigated the impact of semaglutide (Wegovy) and liraglutide (Saxenda) and suggested that semaglutide was more effective at lowering blood sugar levels (as measured by HbA1c).
The study showed that a 0.5mg dose of semaglutide led to a more significant reduction (0.17%) in HbA1c than liraglutide.
The 1mg dose of semaglutide showed a further benefit compared to 1.2mg and 1.7mg of Saxenda at 0.47% and 0.3%, respectively.
However, the studies used to compare the two drugs were from individual trials, comparing one of the medications with a placebo (a sugar pill). They hadn’t yet been compared directly with one another.
Fortunately, a randomised controlled trial was conducted in 2022 investigating the impact of semaglutide and liraglutide on weight loss in individuals living with obesity.
The results showed that the participants in the semaglutide group lost 15.8% of their body weight compared to 6.4% in the liraglutide group.
Semaglutide was also shown to be more tolerated than liraglutide. 13.5% of participants in the semaglutide group discontinued their treatment due to side effects, compared to 27.6% with liraglutide.
Over 80% of participants in both groups reported common side effects and GI-related issues such as constipation, cramping, bloating, and diarrhoea.
Due to the positive results from these studies, Semaglutide was made available in 2023 in the UK after the U.S. approved the drug in 2021.
How does Wegovy compare to weight loss without medication?
Lifestyle interventions without semaglutide tend to lead to an average weight loss of around 5-10%.
Losing and maintaining weight loss of more than 10% is associated with significantly reducing complications related to obesity, including hypertension, type 2 diabetes, and heart disease.
A recent paper published in The Lancet showed that nearly 20% of participants in lifestyle interventions without medications gain weight, around 40% lose between 1-10% of their body weight, and just 13% lose more than 10%.
In comparison, less than 5% of participants combining semaglutide with lifestyle interventions gain weight, around 10% lose between 1-10%, and 87% lose more than 10%.
So, 47% more people lose more than 10% of body weight on lifestyle interventions with semaglutide compared to lifestyle interventions alone.
- A meta-analysis compared the impact of semaglutide and liraglutide on lowering blood sugar levels (measured by HbA1c) and suggested that semaglutide was more effective than liraglutide
- A randomised controlled trial conducted in 2022 investigated the impact of semaglutide and liraglutide on weight loss in individuals living with obesity
- The results showed that semaglutide was more effective at weight loss (15.8% body weight loss) than liraglutide (6.4% body weight loss)
- Semaglutide was also better tolerated than liraglutide, with fewer participants discontinuing treatment due to side effects, but GI-related issues were common in both groups
- Lifestyle interventions without semaglutide average around 5-10% weight loss, and less people achieve clinically significant weight loss without semaglutide
3) What’s the difference between Wegovy and Ozempic?
The only difference between Wegovy and Ozempic® is the available dose, with Wegovy available up to 2.4 mg, compared to 1 mg with Ozempic®.
Initial research on semaglutide focused on Ozempic® and doses between 0.5 mg and 1 mg. However, the studies found that 20-30% of individuals on the medication didn’t reach the treatment targets for reducing their blood sugar levels.
A randomised controlled trial with 961 participants compared the impact of a once-weekly dose of 1mg or 2mg of semaglutide on blood glucose levels and weight loss for people living with type 2 diabetes.
You might expect that a doubling of the dose would lead to a doubling of the effect.
However, the human body is a bit more complex than that. Medications (and hormones in the body) often have a ‘ceiling effect’ where the relationship between the exposure and the effect is no longer linear.
The results showed that 1 mg of semaglutide reduced HbA1c (average blood glucose) by 1.9% compared to 2.2% in the 2 mg group.
A similar trend was shown with weight loss. 1 mg of semaglutide led to an average weight loss of 6 kg compared to 6.9 kg in the 2 mg group. Interestingly, both groups reported similar levels of adverse events and side effects.
So, the higher dose of semaglutide that you’ll receive with Wegovy will likely lead to more significant reductions in weight loss and blood sugar levels without experiencing more adverse events or side effects.
However, you must monitor your medication responses and determine your tolerance level. You might tolerate a higher dose, but you might not.
The research on these medications has shown that the most severe side effects are reported when the dose of the medication is increased while your body adjusts.
You might determine that any side effects are worthwhile to help you improve your health conditions and lose weight. But you must contact your healthcare team and discuss any side effects to ensure this is monitored and the dose adjusted to suit your needs.
- Most research with semaglutide is with the doses of 0.5 mg, and 1mg that you have with Ozempic®
- Only one trial has compared the impact of 1 mg to 2 mg of semaglutide and found it did lead to more significant reductions in weight and blood sugar levels
- However, the differences weren’t as significant as you might expect and the dose that’s best for you will depend on your tolerance level and weight loss goals
- You must report any side-effects with your healthcare team and adjust your dose accordingly
Take home message
The recent innovations in GLP-1 medications are pretty remarkable and have caused quite a stir in the world of healthcare.
We’re in new territory where obesity and type 2 diabetes medications treat an underlying cause instead of merely treating the symptoms to support better management.
However, these weight-loss jabs shouldn’t be seen as miracle cures; they’re not designed to be used for life.
They’ve been designed to be taken alongside lifestyle changes that will enable you to eventually come off the medications and maintain your lower weight for the long term.
The harsh reality is that we still don’t know the long-term effects of these medications on our health. There are examples of drugs being withdrawn from the market as more long-term data comes to light.
Lorcaserin was a weight loss drug approved by the Food and Drug Administration (FDA) in the U.S. but was recently withdrawn as data indicated that it increased cancer risk.
The example of lorcaserin is why you must weigh the pros and cons when your doctor prescribes medication or before you purchase it yourself and start treatment. Report any side effects to your healthcare team.
Wegovy has been shown to be safe and effective for most people in the short to medium term, but we don’t have long-term data to be sure they’re not causing severe adverse effects elsewhere.
At Second Nature, we’re not against using medications to support people in making healthy changes and reducing their risk of chronic disease.
However, we don’t recommend using medications as a reason not to make healthy lifestyle changes. The causes of obesity and type 2 diabetes aren’t merely rooted in biology but also in psychology and sociology.
With these medications, you may lose weight and reduce blood sugar levels. But will you be happier? Will you be more fulfilled? Will you be content with your life and social relationships?
For that, you may need to consider a lifestyle change.
|Second Nature Trustpilot rating
|Second Nature Trustpilot reviews
|6,888 (as of January 2024)
|Once weekly weight-loss injection
|Subcutaneous injection (multiple sites like the arm, stomach, or leg)
|0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg
|GLP-1 receptor agonist